In this article, Technology Networks explores how next-generation tools and techniques are accelerating antibody discovery by overcoming key challenges associated with traditional screening methods.

Experts from Sphere Fluidics*, Thermo Fisher Scientific, and Sino Biological discuss the integration of high-throughput technologies, microfluidics, antibody engineering, and AI/ML-driven tools in improving screening accuracy, speed, and cost-efficiency.

Traditional antibody screening – through phage display or hybridoma methods – is limited by low throughput, false results, and inefficiencies. New solutions, including automated and multiplexed microfluidics platforms, advanced antibody libraries, and AI-assisted design, are helping researchers better identify rare, high-affinity antibody candidates earlier and with less resource expenditure.

* In 2025, Sphere Fluidics became Sphere Bio. References to Sphere Fluidics in this article reflect our former name prior to rebranding.

For more insights on the latest developments in biologics and cell line research, visit Sphere Bio’s Knowledge Hub or or dive into our Cyto-Mine® Chroma solution for early-stage screening.

This article is part of our Editorial Coverage series, showcasing Sphere Bio’s thought leadership and technological contributions in top-tier industry publications. Stay tuned for more.